An Adaptive, Open-Label, Randomized Phase 2 Study of Abemaciclib as a Monotherapy and in Combination With Other Agents Versus Choice of Standard of Care (Gemcitabine or Capecitabine) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma

Trial Profile

An Adaptive, Open-Label, Randomized Phase 2 Study of Abemaciclib as a Monotherapy and in Combination With Other Agents Versus Choice of Standard of Care (Gemcitabine or Capecitabine) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Abemaciclib (Primary) ; Galunisertib (Primary) ; LY 3023414 (Primary) ; Capecitabine; Gemcitabine
  • Indications Adenocarcinoma
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 01 Aug 2017 Planned number of patients changed from 256 to 231.
    • 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 16 Jan 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top